<DOC>
	<DOCNO>NCT00176007</DOCNO>
	<brief_summary>Aim study investigate function systemic vascular endothelium individual susceptible high-altitude pulmonary oedema normoxia normobaric hypoxia .</brief_summary>
	<brief_title>Hypoxia Impairs Endothelial Function HAPEs</brief_title>
	<detailed_description>Rationale : High-altitude pulmonary edema ( HAPE ) characterize excessive pulmonary vasoconstriction associate decreased concentration nitric oxide ( NO ) lung . Objectives : We hypothesize individual susceptible HAPE ( HAPE-S ) would also dysfunction vascular NO vasodilator pathway hypoxia systemic vasculature . Methods : During normoxia ( FI ( O ( 2 ) ) = 0.21 ) 4 hour normobaric hypoxia ( FI ( O ( 2 ) ) = 0.12 , correspond altitude 4,500 sea level ) endothelium-dependent endothelium-independent vasodilator response intraarterial infusion acetylcholine ( ACh ) sodium nitroprusside , respectively , measure forearm venous occlusion plethysmography nine HAPE-S subject nine HAPE-resistant control subject . Main Results : Pulmonary artery systolic pressure increase 22 +/- 3 33 +/- 6 mm Hg ( p &lt; 0.001 ) hypoxia control subject , 25 +/- 4 50 +/- 9 mm Hg HAPE-S subject ( p &lt; 0.001 ) . Despite similar response normoxia group , ACh-induced change forearm blood flow markedly decrease hypoxia HAPE-S subject ( p = 0.01 ) control subject . The attenuated vascular response ACh infusion hypoxia inversely correlate increased pulmonary artery systolic pressure ( p = 0.04 ) decrease plasma nitrite correlate attenuated ACh-induced vasodilation HAPE-S subject ( p = 0.02 ) . Conclusions : Hypoxia markedly impair vascular endothelial function systemic circulation HAPE-S subject due decrease bioavailability NO . Impairment NO pathway could contribute enhanced hypoxic pulmonary vasoconstriction central pathogenesis HAPE .</detailed_description>
	<criteria>Healthy , male volunteer , age : 1855 Able willing give write informed consent Known condition cause endothelial dysfunction ( e.g . diabetes , hyperlipidaemia , arterial hypertension , smoking , hyperhomocysteinaemia ) Regular medication and/or treatment drug within last 4 week ( exclusion decide case ) Acute chronic illness Participation clinical trial/blood donation within 2 month study Nicotine , drug and/or alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2005</verification_date>
</DOC>